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Considering neuroprotective and antioxidant effects of trigonelline, our study was undertaken 
to evaluate its protective effect in a 6-hydroxydopamine-induced model of Parkinson’s disease 
(PD) in rats. Unilateral intrastriatal 6-OHDA-lesioned rats were pretreated with trigonelline 
at doses of 50 and 100 mg/kg. Significant rotational behavior, a significant reduction in the 
number of Nissl-stained neurons on the left side of substantia nigra pars compacta (SNC), 
increased apoptosis, enhanced levels of malondialdehyde (MDA) and nitrite, and a lower 
level of glutathione (GSH) were observed in 6-OHDA-lesioned rats. Trigonelline at a dose of 
100 mg/kg significantly reduced rotations, prevented reduction of SNC neurons, prevented 
apoptosis, and restored the MDA level. These results suggest that pre-lesion trigonelline 
treatment exerts dose-dependent neuroprotective and antiapoptotic effects under conditions 
of 6-OHDA toxicity and may be, henceforth, advantageous for the management of early PD. 
Keywords: Parkinson’s disease, trigonelline, 6-hydroxydopamine, apoptosis, oxidative 
stress.
INTRODUCTION
Parkinson’s disease (PD) is a rather widespread 
neurodegenerative disorder with such cardinal clinical 
symptoms as bradykinesia, rigidity, resting-state 
tremor, postural imbalance, and gait impairment [1]. 
These motor disabilities inevitably lead to a lower 
quality of life [2]. The global occurrence of PD is 
about 0.3% in the general population and 1–2% in 
subjects elder than 60–65 years [2]. Behavioral and 
cognitive problems, including dementia, depression, 
anxiety, and sleep disturbances, also appear within 
late stages of PD [3, 4]. At present, treatment for PD 
includes mainly symptomatics and usually starts with 
Levodopa and/or dopamine agonists [5]. Nevertheless, 
after some time, most PD patients experience side 
effects, including motor and nonmotor fluctuations 
and dyskinesia [6]. 
Oxidative stress-mediated neuronal death plays a 
key role in the pathogenesis of PD [7]. A neurotoxin, 
6-hydroxydopamine (6-OHDA), is routinely used to 
damage mesencephalic dopaminergic neurons and to 
yield a widely used animal model of PD [8]. Because 
environmental factors are engaged in the majority of 
PD cases, it is important to assess the effectiveness 
of natural products in neuroprotective interventions 
for PD [9]. Meanwhile, patients with PD often turn to 
complementary and alternative medicine [10]. 
The alkaloid trigonelline (N-methylnicotinic acid) 
is a metabolite of nicotinic acid. It is mainly found 
in fenugreek seeds and coffee beans. Trigonelline 
demonstrates a potent antioxidant property and strong 
free-radical scavenging activity [11, 12]. This agent 
was shown to attenuate diabetes-induced auditory 
neuropathy [13] and was, in general, reported to 
induce neurite outgrowth and reconstruction of 
neuronal networks in the damaged brain, which is 
exclusively important for the therapeutic treatment 
of neurodegenerative diseases [14]. In addition, a 
standardized extract of fenugreek seeds, which contain 
high amounts of trigonelline, was capable of reversing 
motor dysfunction in rats with 6-OHDA-induced 
unilateral cerebral lesion [15]. For these reasons, 
trigonelline may be regarded as a prospective effective 
mean against PD. Our study was undertaken to assess 
the possible neuroprotective potential of pre-lesion 
trigonelline treatment in the 6-OHDA-induced early 
model of PD in rats.
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METHODS
Chemicals and Reagents. Trigonelline, 6-OHDA, 
apomorphine, Cresyl violet, and oxidative stress kits 
were obtained from Sigma-Aldrich (Germany). All 
other chemicals were procured by Merck (Germany). 
Animals. Adult male Wistar rats (180–210 g, n = 60) 
were provided by the Pasteur’s Institute (Tehran, Iran). 
The animals were housed in a temperature-controlled 
colony room under 12/12 h light/dark cycle with free 
access to food and water and held in the above room for 
at least one week before being tested. Only rats showing 
no rotational behavior (net rotations less frequent than 
30 h–1) were subjected to i.p. injections of apomorphine 
hydrochloride (2 mg/kg) in our study. The animals 
were randomly divided into five groups: (i) sham-
operated; (ii) sham-operated + trigonelline(100); (iii) 
6-OHDA-lesioned; (iv) lesioned + trigonelline(50), and 
(v) lesioned + trigonelline(100; see below). Stereotaxic 
unilateral intrastriatal 6-OHDA injections (left side) were 
performed using a 5 ml Hamilton syringe into anesthetized 
rats (ketamine 80 mg/kg and xylazine 10 mg/kg, i.p.). 
A stereotaxic apparatus (Stoelting, USA) was used 
(coordinates: L –3 mm, AP +9.2 mm, and V +5 mm from 
the center of the interaural line, according to the atlas of 
Paxinos and Watson [16]). After injection, the needle was 
left in place for an additional 5 min and then withdrawn 
at a rate of 1 mm/min. The lesioned groups received 
single injections of 2.5 mg/ml of 6-hydroxydopamine-
HCl in 5 ml of 0.9% saline containing 0.2% ascorbic acid 
(w/v) at a rate of 1 ml/min. The sham group received an 
identical volume of the ascorbate-saline solution. The 
6-OHDA+trigonelline(50) and 6-OHDA+trigonelline 
(100) groups received the neurotoxin in addition to 
trigonelline i.p. dissolved in normal saline at doses of 50 
and 100 mg/kg. Trigonelline was daily administered three 
times before the surgery, with the last injection made 
1 h pre-surgery. The doses of trigonelline were chosen 
according to our preliminary study.
Behavioral Evaluation. The animals (n = 9 in each 
group) were tested for apomorphine hydrochloride 
(2 mg/kg, i.p.)-induced rotational behavior one week 
before surgery (baseline) and at 1st week post-surgery. 
The rotations were measured according to a method 
described previously [8]. Briefly, the animals were 
allowed to habituate for 10 min; then, 1 min after the 
injection, full rotations were counted in a cylindrical 
container (diameter 33 cm and height 35 cm) within 
10-min-long intervals for 60 min (in a dimly-lighted 
and quiet room). Net number of rotations was defined 
as the positive score minus the negative score.
Assessment of Oxidative Stress.  Midbrain 
samples (n = 5 for each group) were dissected from 
the rat brains and washed-off in cold normal saline. 
Their anterior one-thirds were blotted dry, weighed, 
homogenized (5% of tissue) in ice-cold normal saline, 
and centrifuged at 4°C. The obtained supernatant was 
aliquotted and stored at –70°C until being assayed.
Estimation of the MDA Content in the Midbrain. 
The  malondia ldehyde  (MDA) concent ra t ion 
(thiobarbituric acid reactive substances, TBARS) in 
the supernatant was measured as described before [8]. 
Briefly, trichloroacetic acid and a TBARS reagent were 
added to the supernatant, then mixed, and incubated 
at boiling water for 90 min. After cooling on ice, the 
samples were centrifuged at 1000g for 10 min, and the 
absorbance of the supernatant was read at 532 nm. The 
TBARS results were expressed as MDA equivalents 
using tetraethoxypropane as the standard. 
Midbrain Nitrite Assay. The nitrite content in the 
supernatant was assayed by the Griess method accord­
ing to previous studies [17]. Because NO is a com­
pound with a short half-life and is rapidly convert­
ed into stable end products, nitrate (NO
3
–) and nitrite 
(NO
2
–), the principle of the assay is the conversion of 
nitrate into nitrite by cadmium. This is followed by 
color development with the Griess reagent (contain­
ing sulfanilamide and N-naphthyl ethylenediamine) 
in an acidic medium. The total nitrite was measured 
by Griess reaction. The absorbance was measured at 
540 nm with a spectrophotometer.
Catalase Activity Asssay. For this purpose, the 
Claiborne’s method was used [18]. Briefly, H
2
O
2
 was 
added to a mixture of 50 mM potassium phosphate 
buffer (pH 7.0) and supernatant, and the rate of 
H
2
O
2
 decomposition was assessed by measuring the 
absorbance changes at 240 nm for 2 min. One unit of 
the catalase activity was defined as 1.0 μmol of H
2
O
2
 
decomposed within 1 min.
Measurement of the Reduced Glutathione 
(GSH) Level.  The GSH level was measured 
spectrophotometrically as described before [19, 20]. 
Briefly, the supernatant was centrifuged with 5% 
trichloroacetic acid, to centrifuge out the proteins. 
Two milliliters of phosphate buffer (pH 8.4), 0.5 ml 
of 5’5 dithiobis (2-nitrobenzoic acid, DTNB), and 
0.4 ml of bidistilled water were added to 0.1 ml of 
the homogenate. The mixture was vortexed, and the 
absorbance was read at 412 nm within 15 min.
Protein Assay.  The protein content in the 
supernatant was measured with the Bradford method 
using bovine serum albumin as the standard [21].
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F i g. 1: Numbers of apomorphine-induced rotations (within a 
1-h-long observation period) in different groups (A) and decrement/
increment of this index in 6-OHDA-lesioned groups (B). 1–5 are 
indications of the experimental groups (see Methods). *P < 0.05 
in comparison with the control group; + P < 0.05 in comparison of 
groups 4 and 5.
Р и с. 1. Інтенсивність викликаної апоморфіном обертальної 
моторної активності в моделі хвороби Паркінсона, індукованій 
6-OHDA.
Estimation of DNA Fragmentation (Apoptosis). 
In this experiment, three rats from each group were 
euthanized one day after intrastriatal 6-OHDA injection, 
and the midbrain tissue supernatant was prepared 
as above-mentioned. The determination of histone-
associated DNA fragments was performed using the 
Cell Death Detection ELISA kit (Roche Diagnostics, 
Germany) as an indicator of apoptosis according 
to the protocol from the company and the procedure 
as described before [22]. The assay is based on a 
quantitative sandwich-enzyme-immunoassay principle 
using mouse monoclonal antibodies directed against 
DNA and histones, respectively. This allows the specific 
determination of mono- and oligonucleosomes (histone-
associated DNA fragments) in the fraction of tissue 
lysates. The amount of nucleosomes demonstrating 
DNA degradation was quantified by peroxidase retained 
in the immunocomplex. The peroxidase content was 
determined photometrically at 405 nm with 2,2’-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid) as a 
substrate by a microplate reader (BioTek, USA) after 
15 min of the substrate reaction time. The results were 
expressed as the optical density (OD).
Histochemistry. At the end of the study, the rats 
(n = 4 for each group) were deeply anesthetized with 
a high dose of ketamine (150 mg/kg) and perfused 
through the ascending aorta with 50–100 ml of 
0.9% saline followed by 100–150 ml of the fixative 
solution containing 4% paraformaldehyde in 0.1 M 
phosphate buffer (PB, pH 7.4) followed by 100 ml of 
0.1 M PB. After perfusion, the brains were removed 
from the skull; blocks of the forebrain and brainstem 
were prepared, and, after final steps of preparation 
(immersion in 30% sucrose solution for 1–2 days), 
30-mm-thick sections were cut on a freezing 
microtome and collected in PB (0.1 M). Every second 
section was Nissl-stained with 0.1% cresyl violet. 
Histology. For each animal, mesencephalic sections 
(interaural 2.9-4.2 mm) were examined by a method 
described previously [7]. Nissl-stained neurons in the 
SNC were manually counted (light microscopy, ×400) 
using a superimposed grid to facilitate the procedure. 
At least two sections representative of each of four 
Paxinos-Watson planes (4.2, 3.7, 3.2, 2.97, interaural) 
were examined by scanning the entire extent. Counting 
was done blind to the treatments received. 
Statistical Analysis. All data are expressed as 
means ± s.e.m. For statistical evaluation of the data, 
the parametric one-way ANOVA followed by the 
Tukey’s post­hoc test was used. In all analyses, the 
null hypothesis was rejected at P < 0.05.
RESULTS 
The beneficial effect of trigonelline at doses of 50 and 
100 mg/kg was evaluated according to apomorphine-
induced rotations for a period of 1 h (Fig. 1). There 
were no significant differences among the groups 
at baseline (before surgery). Statistical analysis of 
the total net number of rotations at the first week 
post-surgery showed that apomorphine injections 
caused a very significant contralateral turning in 
the rats of the 6-OHDA-lesioned group (P < 0.001) 
and induced significant but less intense rotations 
in the 6-OHDA+trigonelline(50) (P < 0.005) and 
6-OHDA+trigonelline(100) groups (P < 0.01) in 
comparison with the sham group. Moreover, the group 
6-OHDA+trigonelline(100) showed a significantly 
smaller number of rotations (P < 0.05) when compared 
to 6-OHDA-lesioned rats. 
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F i g. 2: Total numbers of Nissl-stained neurons on the left side of the substantia nigra within different frontal planes (A), averaged numbers 
of such units in all planes (B), and photomicrographs of the substantia nigra (C) one week after 6-ODHA introduction. SNC and SNR are 
substantia nigra pars compacta and substantia nigra pars reticulate, respectively. *P < 0.05, **P < 0.01 in comparisons with the sham 
group; # P < 0.05, ## P < 0.01 in comparison with the 6-OHDA group with no trigonelline. Designations of the groups are similar to those in 
Fig. 1.
Р и с. 2. Кількості забарвлених, за Ніслем, нейронів у лівій частині компактної зони чорної субстанції (SNC)  у тварин різних 
експериментальних груп.
Findings of Nissl staining (Fig. 2) showed that there 
was no significant difference between the sham and 
sham+trigonelline(100) groups regarding the number 
of Nissl-stained neurons within the left SNC side. In 
addition, a significant reduction was noticed in the 
6-OHDA-lesioned group (P < 0.05). There were no 
significant reductions in the 6-OHDA+trigonelline(50) 
and 6-OHDA+trigonelline(100) groups when compared 
to the sham group. In this respect, the number of 
Nissl-stained neurons on the left side of SNC was 
significantly higher in the 6-OHDA+trigonelline(100) 
group vs. the  6-OHDA-lesioned group (P < 0.05).
With respect to biochemical markers of oxidative 
stress (Fig. 3), 6-OHDA-lesioned rats demonstrated a 
significant elevation of the MDA content (P < 0.05) 
and nitrite amount (P < 0.05), as well as reduction of 
the GSH level (P < 0.05). At the same time, there was 
no significant reduction of the activity of the defensive 
enzyme (catalase) vs. the respective index in the sham 
group. The treatment of lesioned rats with trigonelline 
at a dose of 100 mg/kg significantly lowered only the 
MDA content (P < 0.05). Meanwhile, there were no 
significant changes in the trigonelline(100)-treated 
sham group relatively to sham animals regarding 
these parameters. Furthermore, the measurement 
of chromosomal breakdown of DNA (which is a 
100 μm
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reliable indicator of apoptosis) showed a significant 
increase of DNA fragmentation in 6-OHDA-lesioned 
rats (P < 0.005) vs. the sham group. The trigonelline 
pretreatment at a dose of 100 mg/kg significantly 
reduced this index in comparison to that in the 
6-OHDA group (P < 0.05), as is shown in Fig. 4.
DISCUSSION
In our study, we confirmed that trigonelline pretreat­
ment in the 100 mg/kg daily dose significantly reduces 
apomorphine-induced rotations in the respective mo-
del, increases the viability of SNC neurons, prevents 
their apoptosis, and restores the MDA level in 6-OHDA- 
lesioned rats.
Selective degeneration of dopaminergic neurons 
in patients with PD results from a genetically 
and/or environmentally-induced process of the 
neurodegeneration (mostly in the SNC) [23]. 6-OHDA, 
the agent generally used for PD induction in rodent 
models, is assumed to cause selective degeneration 
of dopaminergic neurons in this structure [24]. The 
unilateral damage of the nigro-striatal dopaminergic 
system, induced by intrastriatal injection of 6-OHDA, 
is followed by a reduction in the striatal dopamine 
level and upregulation of dopaminergic postsynaptic 
receptors at the same side. These changes produce a 
prominent functional and motor asymmetry that can 
be evaluated by direct-acting dopaminergic agonists, 
apomorphine in particular [25]. These rotations 
are considered reliable indicators of nigro-striatal 
dopamine depletion [26]. In our study, significant 
attenuation of apomorphine-induced rotational 
60 40
10
3.0
2.5
2.0
1.5
1.0
0.5
0
15
40
20
6 9
30
8 12
20
10
4 6
2 3
0 0
0 0
*
#
*
*
F i g. 3. Effects of trigonelline on midbrain oxidative stress markers. *P < 0.05 in comparisons with the sham group; # P < 0.05 in comparison 
with the 6-OHDA group with no trigonelline. Designations of the groups are similar to those in Fig. 1.
Р и с. 3. Маркери оксидативного стресу в середньому мозку тварин різних експериментальних груп.
F i g. 4. The effect of trigonelline on DNA fragmentation in 6-OHDA-
lesioned rat. *P < 0.05 in comparisons with the sham group; 
# P < 0.05 in comparison with the 6-OHDA group with no trigonelline. 
Designations of the groups are similar to those in Fig. 1.
Р и с. 4. Вплив попередніх уведень тригонелліну на 
інтенсивність фрагментації ДНК у моделі хвороби Паркінсона, 
індукованій 6-OHDA.
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behavior was observed in trigonelline(100)-pretreated 
6-OHDA-lesioned rats. The observed attenuation 
of rotational behavior in the mentioned group could 
be attributed to a clear neuroprotective effect of 
trigonelline against SNC neurodegeneration and 
maintenance of striatal dopamine at a level that was 
not accompanied with a marked rotational behavior. 
In other words, nigro-striatal neurons within a SNC 
were mainly preserved in the presence of trigonelline 
against neurodegenerative effects induced by the 
neurotoxin 6-OHDA. In agreement with our earlier 
observations, a standardized hydroalcoholic extract 
of Trigonella foenum­graecum seeds, which contains 
considerable amounts of trigonelline, was capable 
of significantly lowering the intensity of induced 
rotations in unilaterally 6-OHDA-lesioned rats and 
to reverse motor dysfunctions, including enhanced 
spontaneous motor activity in 4-phenyl-1,2,3,6-
tetrahydropyridine-induced lesioned mice. These 
effects have been attributed to the neuroprotective 
potential of this mean [15]. 
In addition, an overproduction of free radicals, 
especially of reactive oxygen species, is also 
cons iderab ly  invo lved  in  6 -OHDA-induced 
neurodegeneration [26]. Oxidative stress is among 
most important factors affecting the survival of 
dopaminergic neurons in PD. Neurons crucially 
depend on adequate energy supply produced by 
mitochondria and are simultaneously faced with 
high levels of reactive oxygen species, as well with 
increased levels of free iron. The latter phenomenon 
can promote hydroxyl production [27]. Overloading by 
the free radicals inevitably leads to intensification of 
the process of cell death. In addition, autooxidation of 
dopamine may produce dopamine quinine [28]. The 
formation of such species (semiquinones and other 
free radicals) can especially intensely damage nucleic 
acids, proteins, and membrane lipid components [29]. 
Therefore, the adequate therapeutic approaches should 
be aimed at attenuation of oxidative stress. Free 
radical scavengers may also be helpful in prolonging 
the survival time of dopaminergic neurons [30]. In 
this respect, trigonelline has been demonstrated to 
attenuate neuronal damage and to strongly counteract 
oxidative stress. The measurement of oxidative stress 
markers in our study also showed that trigonelline 
is able to attenuate this stress and to augment the 
antioxidant defensive system in the midbrain. In this 
way, this compound can significantly decrease the 
toxicity of 6-OHDA. This finding is consistent with 
literature data on the antioxidant ability of this mean 
via regulating the antioxidant defense system, as well 
as via suppression of free radical generation [11].
The inflammatory process initiated in the brain 
structures is also an important causative factor for 
PD [31, 32]. Pro-inflammatory cytokines released 
from glial cells can considerably stimulate nitric 
oxide production and exert a deleterious effect on 
dopaminergic neurons by activating receptors that 
contain intra-cytoplasmic death domains involved 
in the apoptotic pathway [33]. It has been shown 
that coffee (a food product that also contains high 
amounts of trigonelline) demonstrates noticeable 
anti-inflammatory activity [11]. Thus, it is possible 
that trigonelline may also lowered the level of the 
respective “PD-related” inflammatory mediators 
within the brain, and this also contributes in some a 
way to neuroprotection in 6-OHDA-induced PD model 
in rats, as was observed in our study. In addition, 
apoptosis is another factor that plays a critical role 
when cells are exposed to neurotoxins, including 
6-OHDA [34]. In our study, trigonelline was able 
to prevent apoptosis, as evidenced by a lower DNA 
fragmentation. The anti-apoptotic effect of trigonelline 
has also been reported before [35]. Nevertheless, 
some aspects of the respective issue need further 
investigation.
Taken together, our results demonstrated that pre-
lesion treatment with trigonelline in the animal 
model of PD exert, in a dose-dependent manner, clear 
neuroprotective and antiapoptotic effects against 
6-OHDA toxicity. Henceforth, the above agent may be 
included in a set of therapeutic means advantageous 
for the management of early PD. 
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Р е з ю м е
Беручи до уваги нейропротекторний та антиоксидантний 
вплив тригонелліну, ми дослідили його захисну дію в мо­
делі хвороби Паркінсона у щурів, індукованій стереотак­
сичним уведенням 6-гідроксидофаміну (6-OHDA). Щурам, 
котрим робили унілатеральні ін’єкції 6-OHDA в стріатум, 
попередньо щоденно тричі вводили тригонеллін у дозах 50 
і 100 мг/кг. В умовах використаної 6-OHDA-моделі істот­
но посилювалась обертальна моторна поведінка, виклика­
на ін’єкцією апоморфіну, значно знижувалася кількість за­
барвлених, за Ніслем, нейронів у лівій половині компактної 
частини чорної субстанції, посилювався процес апопто­
зу нейронів, зростали рівні малональдегіду та нітриту та 
знижувався рівень відновленого глутатіону. Тригонеллін 
у щоденних дозах 100 мг/кг вірогідно знижував кількість 
обертальних рухів, протидіяв зменшенню числа нейронів у 
чорній субстанції та розвитку апоптозу, а також нормалі­
зував рівень малональдегіду. Отримані результати свідчать 
про те, що уведення тригонелліну перед ін’єкціями 6-OHDA 
забезпечує дозозалежні нейропротекторний та антиапопто­
тичні ефекти в умовах токсичної дії 6-OHDA. Цей агент та 
його аналоги можуть бути тестовані як допоміжні засоби 
при лікуванні хвороби Паркінсона на ранніх стадіях. 
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